OpenLB
Open Library of Bioscience
Advanced Search
Hypertension research : official journal of the Japanese Society of Hypertension
Mar 26, 2025;

Is lenvatinib-induced blood pressure elevation a favorable prognostic factor in patients with hepatocellular carcinoma?

Satoshi Kidoguchi
Author Information
  1. Satoshi Kidoguchi: Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. adversity-makes-hero@goo.jp.
PMID: 40133636 DOI: 10.1038/s41440-025-02197-w

Abstract

Lenvatinib, a multi-tyrosine kinase inhibitor approved for the treatment of multiple cancer types, can induce hypertension, which can be a prognostic indicator in patients with hepatocellular carcinoma. Further research into the mechanism of anticancer drug-induced blood pressure elevation is necessary and patients should be managed by a multi-disciplinary "Onco-Hypertension" team.

Keywords

Cancer Hypertension Onco-hypertension

References

  1. Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8:420���44. [DOI: 10.1001/jamaoncol.2021.6987]
  2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12���49. [DOI: 10.3322/caac.21820]
  3. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23:460���8. [DOI: 10.1038/ajh.2010.25]
  4. Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, et al. New Concept of Onco-Hypertension and Future Perspectives. Hypertension. 2021;77:16���27. [DOI: 10.1161/HYPERTENSIONAHA.120.16044]
  5. Suyama K, Iwase H. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018;25:1073274818789361. [DOI: 10.1177/1073274818789361]
  6. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163���73. [DOI: 10.1016/S0140-6736(18)30207-1]
  7. Shibata K, Akasaki Y, Tokushige A, Nitta M, Kawasoe S, Kubozono T, et al. Blood Pressure Elevations Post-Lenvatinib Treatment in Hepatocellular Carcinoma: A Potential Marker for Better Prognosis. Hypertens Res. 2025. https://doi.org/10.1038/s41440-025-02149-4 .
  8. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763���73. [DOI: 10.1093/jnci/djr128]
  9. Weaver KE, Dressler EV, Smith S, Nightingale CL, Klepin HD, Lee SC, et al. Cardiovascular health assessment in routine cancer follow-up in community settings: survivor risk awareness and perspectives. BMC Cancer. 2024;24:158. [DOI: 10.1186/s12885-024-11912-8]
  10. Ngo DTM, Williams T, Horder S, Kritharides L, Vardy J, Mandaliya H, et al. Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab. J Clin Med. 2020;9:2664. [DOI: 10.3390/jcm9082664]
  11. Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, et al. Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. J Hematol Oncol. 2022;15:92. [DOI: 10.1186/s13045-022-01302-7]
  12. Li W, Wang Z, Jiang C, Hua C, Tang Y, Zhang H, et al. Effect of Intensive Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors. Hypertension. 2024;81:620���8. [DOI: 10.1161/HYPERTENSIONAHA.123.22194]
  13. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912���4018. [DOI: 10.1093/eurheartj/ehae178]
  14. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235���481. [DOI: 10.1038/s41440-019-0284-9]
  15. Plummer C, Michael A, Shaikh G, Stewart M, Buckley L, Miles T, et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Br J Cancer. 2019;121:109���16. [DOI: 10.1038/s41416-019-0481-y]
  16. Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80:e46���57. [DOI: 10.1161/HYP.0000000000000224]
  17. Camarda N, Travers R, Yang VK, London C, Jaffe IZ. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. Curr Oncol Rep. 2022;24:463���74. [DOI: 10.1007/s11912-022-01224-0]
  18. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management. JACC CardioOncol. 2019;1:238���51. [DOI: 10.1016/j.jaccao.2019.11.009]
  19. Fan F, Tian C, Tao L, Wu H, Liu Z, Shen C, et al. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway. Biomed Pharmacother. 2016;83:704���11. [DOI: 10.1016/j.biopha.2016.07.039]
  20. Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, et al. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013;48:491���503. [DOI: 10.1007/s00535-012-0651-7]
Editorial Comment

Word Cloud

Created with Highcharts 10.0.0patientscanprognostichepatocellularbloodpressureelevationLenvatinibmulti-tyrosinekinaseinhibitorapprovedtreatmentmultiplecancertypesinducehypertensionindicatorcarcinomaresearchmechanismanticancerdrug-inducednecessarymanagedmulti-disciplinary"Onco-Hypertension"teamlenvatinib-inducedfavorablefactorcarcinoma?CancerHypertensionOnco-hypertension

Similar Articles

Cited By

No available data.